MK-0646 (MK), insulin growth factor 1 receptor (IGF-1R) antibody combined with pemetrexed (P) and cisplatin (C) in stage IIIb or IV metastatic nonsquamous lung cancer (NSQL). This is an ASCO Meeting ...
The MarketWatch News Department was not involved in the creation of this content. -- PEGASUS(TM) is an industry-first in peptide design: It achieves AI-driven generative design of the first permeable ...
Insamo Inc., founded in 2022 to combine machine-learning capabilities, high-throughput screening and genetic engineering to create orally administered membrane-permeable cyclic peptides across a range ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Orbis Medicines emerged from stealth Feb. 29 with $28 million in seed funding. The company is the latest launched to turn cyclic peptide molecules into orally available drugs that could replace ...
The Tat-SIRT5-CTM peptide specifically blocked the interaction of SIRT5 with ANXA1, led to SIRT5 degradation and thereby inhibiting SIRT5-mediated desuccinylation of ANXA1, which in turn alleviated ...
For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation ...
PEGASUS™ is an industry-first in peptide design: It achieves AI-driven generative design of the first permeable macrocyclic peptide with more than two polar or ionizable fragments. Surrogate assays ...
To understand the focus of startup Insamo Inc., one need look no further than its name, which co-founder and CEO Timothy Craven described as “portmanteau of ‘internally satisfied molecules,’” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results